The Impact of the Metabolic Syndrome on Neuropathy

代谢综合征对神经病变的影响

• 批准号: 8876827
• 负责人: Brian Christopher Callaghan
• 金额: $ 18.84万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-07-01 至 2016-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8876827
• 关键词: Address; Affect; Age; American; Area; Biopsy; Blood Pressure; Classification; Clinic; Clinical; Clinical Trials; Consensus; Coupled; Cross-Sectional Studies; Development; Diabetes Mellitus; Diabetic Neuropathies; Diagnosis; Diagnostic tests; Disease; Distal; Enrollment; Epidemiology; Etiology; Evaluation; Evolution; Fiber; Future; Gender; Glucose; Goals; Health; High Density Lipoprotein Cholesterol; Hypertriglyceridemia; Idiopathic Neuropathy; Individual; Institutes; Intervention; Investigation; K-Series Research Career Programs; Label; Lead; Leg; Logistic Regressions; Measures; Mentors; Metabolic; Metabolic syndrome; Michigan; Modeling; Nerve Fibers; Neurologic; Neuropathy; Non-Insulin-Dependent Diabetes Mellitus; Obesity; Observational Study; Outcome; Outcome Measure; Pain; Patients; Pharmaceutical Preparations; Phenotype; Population; Prediabetes syndrome; Predictive Factor; Prevalence; Public Health Schools; Regimen; Relative Risks; Research; Research Design; Research Infrastructure; Research Personnel; Resources; Risk; Risk Factors; Risk Reduction; Serum; Skin; Staging; Syndrome; Testing; Thigh structure; Time; Training; United States National Institutes of Health; Universities; Weight maintenance regimen; base; blood glucose regulation; cardiovascular disorder risk; cardiovascular risk factor; career development; cohort; density; design; diabetic; diet and exercise; effective therapy; experience; longitudinal analysis; longitudinal design; modifiable risk; prevent; primary outcome; sugar

DESCRIPTION (provided by applicant): Neuropathy is a painful and debilitating condition that affects over 15 million Americans. Surprisingly over 30% of patients are labeled as idiopathic even after an extensive evaluation. For those patients with the most common cause of neuropathy, diabetes, glucose control remains the only effective treatment. Unfortunately, greater than 40 percent of patients with diabetes will develop neuropathy despite good glucose control. These observations highlight the need to identify modifiable risk factors for neuropathy that may be the cause of "idiopathic" neuropathy and the factors that in addition to high serum glucose lead to diabetic neuropathy. Metabolic syndrome components may be these important modifiable risk factors in neuropathy. This syndrome is comprised of multiple cardiovascular risk factors that tend to cluster together. Past observational studies have implicated one or more of these components in the development of neuropathy, but these studies have suffered from significant design limitations. Most studies were only cross-sectional in design and focused only on diabetic populations. Furthermore, these studies did not apply a standardized definition of neuropathy, and case classification was often based on one diagnostic test. In this career development award, we propose to quantify the impact of the metabolic syndrome on neuropathy and to determine which metabolic syndrome components are associated with neuropathy in two specific aims. In aim 1, we will compare the prevalence of neuropathy in a metabolic syndrome cohort with lean controls by utilizing extensive neuropathy phenotyping. In aim 2, we will employ cross-sectional and longitudinal designs to identify which metabolic syndrome components are associated with neuropathy. The cross-sectional design has the advantage of applying clinical neuropathy outcome measures prior to any intervention. The advantage of the longitudinal component is that we can investigate the relationship of the dynamic changes in metabolic syndrome components after a diet and exercise regimen with changes in neuropathy outcome measures. The overall goal of this project is to identify modifiable risk factors for the development of neuropathy that will lead to interventional clinical trials to prevent and/or treat neuropathy. This proposal is essential to my career development. I will become an independent clinical researcher with expertise in neurologic complications from endocrinologic disease states. The biostatistician and epidemiologic formal training and practical experiences will set the stage for successful completion of not only this project, but also of future investigations. The clinical trial component of my career development will allow me to take the results from this study and seamlessly transition into interventional studies that will lead to new treatments for patients with neuropathy. Drs. Eva Feldman and Charles Burant are ideally suited as mentors for this project with their complementary expertise in neuropathy and metabolic phenotyping. The vast resources of the University of Michigan, including the Neuropathy Center, the Investigational Weight Management Clinic, the Michigan Institute for Clinical and Health Research, and the school of Public Health, will significantly contribute to the successful completion of this proposal.

描述（由申请人提供）：神经病变是一种痛苦和衰弱的疾病，影响超过1500万美国人。令人惊讶的是，超过30%的患者被标记为特发性，即使经过广泛的评估。对于那些最常见的神经病变，糖尿病，血糖控制仍然是唯一有效的治疗方法。不幸的是，超过40%的糖尿病患者会发展为神经病变，尽管血糖控制良好。这些观察结果强调需要确定神经病变的可改变的危险因素，这些因素可能是“特发性”神经病变的原因，以及除高血糖外导致糖尿病性神经病变的因素。代谢综合征成分可能是神经病变中这些重要的可改变的危险因素。这种综合征由多种心血管危险因素组成，这些因素往往聚集在一起。过去的观察性研究暗示了神经病变发展中的一个或多个因素，但这些研究在设计上存在明显的局限性。大多数研究在设计上只是横截面的，并且只关注糖尿病人群。此外，这些研究没有应用神经病变的标准化定义，病例分类通常基于一种诊断测试。在这个职业发展奖项中，我们提出量化代谢综合征对神经病变的影响，并确定哪些代谢综合征成分与神经病变有两个特定的目标。在目的1中，我们将利用广泛的神经病变表型，比较代谢综合征队列中神经病变的患病率与瘦对照。在目标2中，我们将采用横断面和纵向设计来确定哪些代谢综合征成分与神经病变相关。横断面设计具有在任何干预之前应用临床神经病变结果测量的优势。纵向成分的优势在于，我们可以研究饮食和运动方案后代谢综合征成分的动态变化与神经病变结局测量的变化之间的关系。该项目的总体目标是确定神经病变发展的可改变的危险因素，这些因素将导致介入临床